- Home
- MORN vs MRNA Comparison
MORN vs MRNA Comparison
Compare MORN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MORN | MRNA |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.3B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MORN | MRNA |
|---|---|---|
| Price | $217.81 | $27.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 13 |
| Target Price | ★ $333.33 | $33.91 |
| AVG Volume (30 Days) | 296.7K | ★ 9.9M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ 16.18 | N/A |
| EPS | ★ 8.80 | N/A |
| Revenue | ★ $2,395,400,000.00 | $2,232,000,000.00 |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $7.52 | $0.77 |
| P/E Ratio | $24.81 | ★ N/A |
| Revenue Growth | ★ 7.76 | N/A |
| 52 Week Low | $202.89 | $22.28 |
| 52 Week High | $365.00 | $48.92 |
Technical Indicators
Market Signals| Indicator | MORN | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 60.85 |
| Support Level | $213.53 | $23.92 |
| Resistance Level | $219.62 | $26.00 |
| Average True Range (ATR) | 4.43 | 1.29 |
| MACD | 1.32 | 0.32 |
| Stochastic Oscillator | 89.38 | 99.82 |
Price Performance
Historical ComparisonAbout MORN Morningstar Inc.
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.